Capital with purpose: How capital markets are shaping the future of medicine with Dheeraj Chinthalapelly

The Indian biotech and pharmaceutical sectors are poised for growth, driven by innovation and increasing capital market interest. This trend could lead to higher valuations and M&A activity.

Consider long positions in fundamentally strong Indian biotech and pharma companies with a focus on R&D and innovation, with a stop-loss below recent support levels.

For Indian markets, this story mainly matters for the Biotechnology, Pharmaceuticals, Financial Services pocket. The current signal is bullish, so traders should watch whether the effect spreads across the sector or stays limited to a single name.

Watch whether the market validates this read through price action, volume, and breadth. If the headline matters, the signal should show up in execution, not just in commentary.

• •Dheeraj Chinthalapelly has 15 years of experience in global capital markets, focusing on biotech investment banking.
• •He emphasizes capital raising and M&A in the biotech sector.
• •He highlights advising companies that bring scientific innovation to patients and prioritizing long-term value creation.
• •Risk flag: Regulatory changes in the pharmaceutical sector
• •Risk flag: Global economic slowdown impacting investment flows